Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.70 |
| ▸ | KDR | P35968 | 4/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7224748 | 0.90 | EGFR (0.56) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL1386469 | 0.90 | EGFR (0.56) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL3076337 | 0.90 | EGFR (0.84) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL7227407 | 0.87 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL7227388 | 0.87 | KDR (0.55) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL7226004 | 0.87 | KDR (0.55) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL7227412 | 0.87 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL7227393 | 0.87 | KDR (0.55) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL7226007 | 0.87 | EGFR (0.60) | EGFRERBB2 | |
| SCHEMBL7226011 | 0.87 | EGFR (0.60) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | EGFR 137/4885KDR 500/4885HDAC3 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.